Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 5Neoplasm Metastasis 3Relapsed Pediatric Solid Tumor 1NSCLC 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 9Oxaliplatin 6Cisplatin 6Capecitabine 6durvalumab 4apatinib 4S 1 (combination) 4Irinotecan 4Immune Checkpoint Inhibitors 4surufatinib 3Injections 3Drug Therapy 3pembrolizumab 2lenvatinib 2camrelizumab 2Taxes 2Leucovorin 2Fluorouracil 2Docetaxel 2130-nm albumin-bound paclitaxel 2tremelimumab 1toripalimab 1taxane 1spartalizumab 1sintilimab 1regorafenib 1manganese chloride 1irinotecan sucrosofate 1gimeracil 1gemcitabine-oxaliplatin regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Biliary Tract Neoplasms × Axitinib × Clear all
NCT04010071 2023-03-29

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Peking Union Medical College Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡